title: Mucinous adenocarcinoma arising from a residual supratentorial neurenteric cyst and expressing mutated KRAS: a case report.
abstract: Malignant transformation of intracranial neurenteric cysts (NCs) has been reported in only 7 cases, but the molecular characteristics leading to malignant transformation remain unclear. A 61-year-old woman presented with headache and dizziness. Imaging revealed a 10-cm, extra-axial cystic mass in both middle fossae. A partial resection was performed, and the residual mass size gradually decreased. She had repeated ventriculoperitoneal shunts to relieve symptoms of hydrocephalus. Eight years later, follow-up images revealed marked enlargement of the mass and a newly developed lesion. After a second partial resection, a mucinous adenocarcinoma infiltrating the brain was identified. Transitions from benign-looking cuboidal cells to dysplastic cells were observed. A KRAS mutation, which might be associated with malignant NC transformation and was not present in the initial specimen, was identified in the adenocarcinoma. In conclusion, KRAS-mutant mucinous adenocarcinoma may arise in a longstanding residual NC after partial resection.
authors: Department of Neurosurgery, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 431-070, Republic of Korea.
authors: Hyun Taek
authors: HT
authors: Rim
authors: Department of Neurosurgery, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 431-070, Republic of Korea.
authors: Joon Ho
authors: JH
authors: Song
authors: Department of Radiology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 431-070, Republic of Korea. Electronic address: silwater007@hallym.or.kr.
authors: Eun Soo
authors: ES
authors: Kim
authors: Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 431-070, Republic of Korea. Electronic address: mulank@hanmail.net.
authors: Mi Jung
authors: MJ
authors: Kwon
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000737:chemistry / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D002471:Cell Transformation, Neoplastic / Q000737:chemistry / Q000235:genetics* / Q000473:pathology; D004252:DNA Mutational Analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009154:Mutation; D009436:Neural Tube Defects / Q000473:pathology* / Q000601:surgery; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D015173:Supratentorial Neoplasms / Q000737:chemistry / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; C117307:KRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)
keywords: Adenocarcinoma; Immunohistochemistry; KRAS; Mutation; Neurenteric cyst; Recurrence